基因治疗 z-bo 2020-11-13 347

　　Objective: To study the effect of TGF-β1 gene therapy on the rat model of postpartum stress urinary incontinence, and to explore an ideal new non-surgical treatment for the disease.

　　Methods: Model 240 female SD rats with water sac vaginal dilation method, 148 were randomly selected from 185 successful models and divided into 5 groups, and were treated with TGF-β1 gene therapy, aminotransferase drug therapy, electrical stimulation therapy, Empty plasmid vector injection and untreated, another 20 unestablished rat models were selected as blank controls, sneezing experiments, urodynamic testing, and pelvic pubococcygeus muscle strength were performed 1, 21, 42 d and 63 d after treatment /Muscle weight ratio, ELISA method to detect TGF-1, immunohistochemical detection factor TGF-β1.

　　Results: 21 days after treatment, the TGF-β1 gene therapy group had better therapeutic effects, no matter the maximum bladder capacity, leakage point pressure, or contractile force/muscle weight ratio, and there was no significant difference between the TGF-β1 gene therapy group and the electrical stimulation group. Sex (P>0.05).

　　Conclusion: TGF-β1 gene therapy may become a new non-surgical treatment method, which can produce good effects on rats with postpartum stress urinary incontinence.